Publications by authors named "B Jonas"

Claim this Profile
O
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A Jonas, Radovan Vrhovac

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, Brian A Jonas, Neil Dunavin

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.
Jorge Cortes, Antonio Curti, Pierre Fenaux, Brian A Jonas, Jürgen Krauter

J Hematol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).
Brian A Jonas, Samantha C Fisch, Peter T Curtin, Gary J Schiller, Deepa Jeyakumar

Leuk Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The greatest potential for reducing the workload of physicians through digital care applications (DiPAs) lies within the age group of 50 to 65 years].
Doreen Müller, Julie Lorraine OʼSullivan, Mandy Schulz, Tobias Nieporte, Benjamin Jonas

Gesundheitswesen· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis